BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/3/2024 7:21:13 AM | Browse: 389 | Download: 652
Publication Name World Journal of Gastroenterology
Manuscript ID 91396
Country United States
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Cell Biology
Manuscript Type Editorial
Article Title Recent clinical trials and optical control as a potential strategy to develop microtubule-targeting drugs in colorectal cancer management
Manuscript Source Invited Manuscript
All Author List Katsuhiro Kita and Allen Burdowski
ORCID
Author(s) ORCID Number
Katsuhiro Kita http://orcid.org/0000-0001-7392-1722
Funding Agency and Grant Number
Corresponding Author Katsuhiro Kita, PhD, Assistant Professor, Department of Biology, St. Francis College, 179 Livingston Street, Brooklyn, NY 11201, United States. kkita@sfc.edu
Key Words Colorectal cancer; Chemotherapy; Microtubule; Combretastatin; Photopharmacology
Core Tip This review article proposes a potentially new approach to utilize photo-switchable microtubule (MT)-targeting drugs in colorectal cancer (CRC). First, we will start the introduction of CRC and current therapy as well as some updates in 2023. Then, we list a popular MT-targeting drug family, taxanes in CRC. As many readers may be aware, taxanes are not really effective in CRC for some reason. Here, we would like to shed light on optically controllable MT-targeting drugs as potential new drug candidates in CRC management.
Publish Date 2024-04-03 07:21
Citation Kita K, Burdowski A. Recent clinical trials and optical control as a potential strategy to develop microtubule-targeting drugs in colorectal cancer management. World J Gastroenterol 2024; 30(13): 1780-1790
URL https://www.wjgnet.com/1007-9327/full/v30/i13/1780.htm
DOI https://dx.doi.org/10.3748/wjg.v30.i13.1780
Full Article (PDF) WJG-30-1780-with-cover.pdf